Development
Tarsus Pharmaceuticals, Inc.
TARS
$41.46
-$0.45-1.07%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 13.08M | 1.87M | -- | 2.50M | 10.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.08M | 1.87M | -- | 2.50M | 10.00M |
| Cost of Revenue | 14.52M | 12.48M | 12.55M | 12.36M | 10.43M |
| Gross Profit | -1.45M | -10.61M | -12.55M | -9.86M | -428.00K |
| SG&A Expenses | 43.01M | 30.32M | 20.28M | 15.10M | 14.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.53M | 42.81M | 32.82M | 27.45M | 25.06M |
| Operating Income | -44.45M | -40.94M | -32.82M | -24.95M | -15.06M |
| Income Before Tax | -41.90M | -39.15M | -31.42M | -23.42M | -13.60M |
| Income Tax Expenses | -- | -- | -- | -- | 0.00 |
| Earnings from Continuing Operations | -41.90M | -39.15M | -31.42M | -23.42M | -13.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.90M | -39.15M | -31.42M | -23.42M | -13.60M |
| EBIT | -44.45M | -40.94M | -32.82M | -24.95M | -15.06M |
| EBITDA | -44.10M | -40.69M | -32.64M | -24.85M | -14.96M |
| EPS Basic | -1.31 | -1.28 | -1.17 | -0.88 | -0.51 |
| Normalized Basic EPS | -0.77 | -0.80 | -0.73 | -0.55 | -0.32 |
| EPS Diluted | -1.31 | -1.28 | -1.17 | -0.88 | -0.51 |
| Normalized Diluted EPS | -0.77 | -0.80 | -0.73 | -0.55 | -0.32 |
| Average Basic Shares Outstanding | 31.94M | 30.62M | 26.82M | 26.74M | 26.71M |
| Average Diluted Shares Outstanding | 31.94M | 30.62M | 26.82M | 26.74M | 26.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |